Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 4
1985 2
1986 1
1987 2
1988 2
1989 3
1990 3
1991 2
1992 2
1993 2
1994 6
1995 6
1996 4
1997 8
1998 3
1999 5
2000 4
2001 3
2002 13
2003 5
2004 8
2005 12
2006 3
2007 9
2008 5
2009 10
2010 15
2011 13
2012 6
2013 15
2014 13
2015 15
2016 8
2017 15
2018 7
2019 12
2020 13
2021 9
2022 13
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Results by year

Filters applied: . Clear all
Page 1
Endothelial-to-mesenchymal transition in pulmonary hypertension.
Ranchoux B, Antigny F, Rucker-Martin C, Hautefort A, Péchoux C, Bogaard HJ, Dorfmüller P, Remy S, Lecerf F, Planté S, Chat S, Fadel E, Houssaini A, Anegon I, Adnot S, Simonneau G, Humbert M, Cohen-Kaminsky S, Perros F. Ranchoux B, et al. Among authors: anegon i. Circulation. 2015 Mar 17;131(11):1006-18. doi: 10.1161/CIRCULATIONAHA.114.008750. Epub 2015 Jan 15. Circulation. 2015. PMID: 25593290
Gene therapy. Preface.
Anegon I. Anegon I. Curr Gene Ther. 2013 Feb;13(1):1. doi: 10.2174/156652313804806589. Curr Gene Ther. 2013. PMID: 23658935 No abstract available.
Immunoregulatory properties of the cytokine IL-34.
Guillonneau C, Bézie S, Anegon I. Guillonneau C, et al. Among authors: anegon i. Cell Mol Life Sci. 2017 Jul;74(14):2569-2586. doi: 10.1007/s00018-017-2482-4. Epub 2017 Mar 3. Cell Mol Life Sci. 2017. PMID: 28258292 Review.
Effector mechanisms of rejection.
Moreau A, Varey E, Anegon I, Cuturi MC. Moreau A, et al. Among authors: anegon i. Cold Spring Harb Perspect Med. 2013 Nov 1;3(11):a015461. doi: 10.1101/cshperspect.a015461. Cold Spring Harb Perspect Med. 2013. PMID: 24186491 Free PMC article. Review.
Future prospects for CD8+ regulatory T cells in immune tolerance.
Flippe L, Bézie S, Anegon I, Guillonneau C. Flippe L, et al. Among authors: anegon i. Immunol Rev. 2019 Nov;292(1):209-224. doi: 10.1111/imr.12812. Epub 2019 Oct 8. Immunol Rev. 2019. PMID: 31593314 Free PMC article. Review.
Predictive immunomonitoring -- the COST ENTIRE initiative.
Popadic D, Anegon I, Baeten D, Eibel H, Giese T, Marits P, Martinez-Caceres E, Mascart F, Nestle F, Pujol-Borrell R, Savic E, Scheibenbogen C, Seliger B, Thunberg S, Turina M, Villanova F, Winqvist O, Wikström AC. Popadic D, et al. Among authors: anegon i. Clin Immunol. 2013 Apr;147(1):23-26. doi: 10.1016/j.clim.2013.01.013. Epub 2013 Feb 8. Clin Immunol. 2013. PMID: 23454893 No abstract available.
Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy.
Le Guiner C, Xiao X, Larcher T, Lafoux A, Huchet C, Toumaniantz G, Adjali O, Anegon I, Remy S, Grieger J, Li J, Farrokhi V, Neubert H, Owens J, McIntyre M, Moullier P, Samulski RJ. Le Guiner C, et al. Among authors: anegon i. Mol Ther Methods Clin Dev. 2023 May 18;30:30-47. doi: 10.1016/j.omtm.2023.05.017. eCollection 2023 Sep 14. Mol Ther Methods Clin Dev. 2023. PMID: 37746247 Free PMC article.
270 results